RE:TIGIT class of checkpoint inhibitors fails with Keytruda April 27, 2023 - Roche is "tightlipped" on another TIGIT possible failure ..... as they dodged questions about whether their candidate has flunked yet another phase 3 trial.
Roche needs to add ONCY's pelareorep to stimulate the immune system and convert an immunosuppressive tumor microenvironment (TME) to facilitate the TIGIT and PD-1 immune checkpoint inhibitor tecentriq combination that has yet to prove effective.
https://www.fiercebiotech.com/biotech/roche-tightlipped-possible-tiragolumab-fail-pledges-more-tigit-trials-anyway